To arrange an interview, please contact the NHLBI Communications Office at 301-496-4236 or firstname.lastname@example.org.
Neal S. Young, M.D., joined the National Heart, Lung, and Blood Institute (NHLBI) in 1981. He is Chief of the Institute's Intramural Research Hematology Branch. Dr. Young's research interests are in human hematopoiesis, aplastic anemia and the pathogenesis and treatment of bone marrow failure; parvoviruses, hepatitis viruses, immune response to virus infection, apoptosis, interferon, cytokines, and other interleukins, and the mechanisms of genomic instability. His research includes direct patient care and clinical protocols for the treatment of bone marrrow failure; basic science laboratory experiments involving normal and abnormal blood cell production; and epidemiologic studies of aplastic anemia.
Dr. Young received an M.D. in 1971 from the Johns Hopkins School of Medicine in Baltimore, MD. He received an A.B. cum laude from Harvard College in Boston, MA in 1967. He did post-graduate medical training at Massachusetts General Hospital and Barnes Hospital at Washington University in St. Louis, MO.
Dr. Young has authored 270 original scientific and medical articles in peer reviewed journals and more than 120 reviews and chapters. He also is author or editor of 10 medical and scientific books. including a new textbook of hematology. He is co-inventor on 7 patents concerning B19 parvovirus. Dr. Young is a member of the American Society for Clinical Investigation, the American Association of Physicians, the American Federation for Clinical Research, the American Society of Hematology, and the International Society for Experimental Hematology. Dr. Young also is a Master of the American College of Physicians.
October 22, 2012
: Elsevier Connect
Finding cures for mystery diseases
NIH researcher and Elsevier editor Neal S. Young honored for solving aplastic anemia and other medical puzzles.
October 5, 2012
The NIH doctor who pioneered life-saving treatments
The Partnership for Public Service
For years, patients with severe aplastic anemia died within months of developing the rare blood disease. Dr. Neal Young has increased the survival rate to 80 percent.
Clinical Trials for Rare Blood Diseases (Neal Young, M.D.)